Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome

Roland Därr, Joan Nambuba, Jaydira Del Rivero, Ingo Janssen, Maria Merino, Milena Todorovic, Bela Balint, Ivana Jochmanova, Josef T. Prchal, Ronald M. Lechan, Arthur S. Tischler, Vera Popovic, Dragana Miljic, Karen T. Adams, F. Ryan Prall, Alexander Ling, Meredith Golomb, Michael Ferguson, Naris Nilubol, Clara C. Chen & 8 others Emily Chew, David Taïeb, Constantine A. Stratakis, Tito Fojo, Chunzhang Yang, Electron Kebebew, Zhengping Zhuang, Karel Pacak

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Worldwide, the syndromes of paraganglioma (PGL), somatostatinoma (SOM) and early childhood polycythemia are described in only a few patients with somatic mutations in the hypoxia-inducible factor 2 alpha (HIF2A). This study provides detailed information about the clinical aspects and course of 7 patients with this syndrome and brings into perspective these experiences with the pertinent literature. Six females and one male presented at a median age of 28 years (range 11-46). Two were found to have HIF2A somatic mosaicism. No relatives were affected. All patients were diagnosed with polycythemia before age 8 and before PGL/SOM developed. PGLs were found at a median age of 17 years (range 8-38) and SOMs at 29 years (range 22-38). PGLs were multiple, recurrent and metastatic in 100, 100 and 29% of all cases, and SOMs in 40, 40 and 60%, respectively. All PGLs were primarily norepinephrine-producing. All patients had abnormal ophthalmologic findings and those with SOMs had gallbladder disease. Computed tomography (CT) and magnetic resonance imaging revealed cystic lesions at multiple sites and hemangiomas in 4 patients (57%), previously thought to be pathognomonic for von Hippel-Lindau disease. The most accurate radiopharmaceutical to detect PGL appeared to be [18F]-fluorodihydroxyphenylalanine ([18F]-FDOPA). Therefore, [18F]-FDOPA PET/CT, not [68Ga]-(DOTA)-[Tyr3]-octreotate ([68Ga]-DOTATATE) PET/CT is recommended for tumor localization and aftercare in this syndrome. The longterm prognosis of the syndrome is unknown. However, to date no deaths occurred after 6 years follow-up. Physicians should be aware of this unique syndrome and its diagnostic and therapeutic challenges.

Original languageEnglish (US)
Pages (from-to)899-908
Number of pages10
JournalEndocrine-Related Cancer
Volume23
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Somatostatinoma
Paraganglioma
Polycythemia
Tomography
von Hippel-Lindau Disease
Gallbladder Diseases
Aftercare
Mosaicism
Radiopharmaceuticals
Hemangioma
Norepinephrine
Magnetic Resonance Imaging
Physicians
Mutation
Neoplasms

Keywords

  • HIF2A mutation
  • Paraganglioma
  • Pheochromocytoma
  • Polycythemia
  • Somatostatinoma

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Cite this

Därr, R., Nambuba, J., Del Rivero, J., Janssen, I., Merino, M., Todorovic, M., ... Pacak, K. (2016). Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. Endocrine-Related Cancer, 23(12), 899-908. https://doi.org/10.1530/ERC-16-0231

Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. / Därr, Roland; Nambuba, Joan; Del Rivero, Jaydira; Janssen, Ingo; Merino, Maria; Todorovic, Milena; Balint, Bela; Jochmanova, Ivana; Prchal, Josef T.; Lechan, Ronald M.; Tischler, Arthur S.; Popovic, Vera; Miljic, Dragana; Adams, Karen T.; Prall, F. Ryan; Ling, Alexander; Golomb, Meredith; Ferguson, Michael; Nilubol, Naris; Chen, Clara C.; Chew, Emily; Taïeb, David; Stratakis, Constantine A.; Fojo, Tito; Yang, Chunzhang; Kebebew, Electron; Zhuang, Zhengping; Pacak, Karel.

In: Endocrine-Related Cancer, Vol. 23, No. 12, 01.12.2016, p. 899-908.

Research output: Contribution to journalArticle

Därr, R, Nambuba, J, Del Rivero, J, Janssen, I, Merino, M, Todorovic, M, Balint, B, Jochmanova, I, Prchal, JT, Lechan, RM, Tischler, AS, Popovic, V, Miljic, D, Adams, KT, Prall, FR, Ling, A, Golomb, M, Ferguson, M, Nilubol, N, Chen, CC, Chew, E, Taïeb, D, Stratakis, CA, Fojo, T, Yang, C, Kebebew, E, Zhuang, Z & Pacak, K 2016, 'Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome', Endocrine-Related Cancer, vol. 23, no. 12, pp. 899-908. https://doi.org/10.1530/ERC-16-0231
Därr R, Nambuba J, Del Rivero J, Janssen I, Merino M, Todorovic M et al. Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. Endocrine-Related Cancer. 2016 Dec 1;23(12):899-908. https://doi.org/10.1530/ERC-16-0231
Därr, Roland ; Nambuba, Joan ; Del Rivero, Jaydira ; Janssen, Ingo ; Merino, Maria ; Todorovic, Milena ; Balint, Bela ; Jochmanova, Ivana ; Prchal, Josef T. ; Lechan, Ronald M. ; Tischler, Arthur S. ; Popovic, Vera ; Miljic, Dragana ; Adams, Karen T. ; Prall, F. Ryan ; Ling, Alexander ; Golomb, Meredith ; Ferguson, Michael ; Nilubol, Naris ; Chen, Clara C. ; Chew, Emily ; Taïeb, David ; Stratakis, Constantine A. ; Fojo, Tito ; Yang, Chunzhang ; Kebebew, Electron ; Zhuang, Zhengping ; Pacak, Karel. / Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. In: Endocrine-Related Cancer. 2016 ; Vol. 23, No. 12. pp. 899-908.
@article{98fb4ee4662d4db8b2403db6559b12ec,
title = "Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome",
abstract = "Worldwide, the syndromes of paraganglioma (PGL), somatostatinoma (SOM) and early childhood polycythemia are described in only a few patients with somatic mutations in the hypoxia-inducible factor 2 alpha (HIF2A). This study provides detailed information about the clinical aspects and course of 7 patients with this syndrome and brings into perspective these experiences with the pertinent literature. Six females and one male presented at a median age of 28 years (range 11-46). Two were found to have HIF2A somatic mosaicism. No relatives were affected. All patients were diagnosed with polycythemia before age 8 and before PGL/SOM developed. PGLs were found at a median age of 17 years (range 8-38) and SOMs at 29 years (range 22-38). PGLs were multiple, recurrent and metastatic in 100, 100 and 29{\%} of all cases, and SOMs in 40, 40 and 60{\%}, respectively. All PGLs were primarily norepinephrine-producing. All patients had abnormal ophthalmologic findings and those with SOMs had gallbladder disease. Computed tomography (CT) and magnetic resonance imaging revealed cystic lesions at multiple sites and hemangiomas in 4 patients (57{\%}), previously thought to be pathognomonic for von Hippel-Lindau disease. The most accurate radiopharmaceutical to detect PGL appeared to be [18F]-fluorodihydroxyphenylalanine ([18F]-FDOPA). Therefore, [18F]-FDOPA PET/CT, not [68Ga]-(DOTA)-[Tyr3]-octreotate ([68Ga]-DOTATATE) PET/CT is recommended for tumor localization and aftercare in this syndrome. The longterm prognosis of the syndrome is unknown. However, to date no deaths occurred after 6 years follow-up. Physicians should be aware of this unique syndrome and its diagnostic and therapeutic challenges.",
keywords = "HIF2A mutation, Paraganglioma, Pheochromocytoma, Polycythemia, Somatostatinoma",
author = "Roland D{\"a}rr and Joan Nambuba and {Del Rivero}, Jaydira and Ingo Janssen and Maria Merino and Milena Todorovic and Bela Balint and Ivana Jochmanova and Prchal, {Josef T.} and Lechan, {Ronald M.} and Tischler, {Arthur S.} and Vera Popovic and Dragana Miljic and Adams, {Karen T.} and Prall, {F. Ryan} and Alexander Ling and Meredith Golomb and Michael Ferguson and Naris Nilubol and Chen, {Clara C.} and Emily Chew and David Ta{\"i}eb and Stratakis, {Constantine A.} and Tito Fojo and Chunzhang Yang and Electron Kebebew and Zhengping Zhuang and Karel Pacak",
year = "2016",
month = "12",
day = "1",
doi = "10.1530/ERC-16-0231",
language = "English (US)",
volume = "23",
pages = "899--908",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "12",

}

TY - JOUR

T1 - Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome

AU - Därr, Roland

AU - Nambuba, Joan

AU - Del Rivero, Jaydira

AU - Janssen, Ingo

AU - Merino, Maria

AU - Todorovic, Milena

AU - Balint, Bela

AU - Jochmanova, Ivana

AU - Prchal, Josef T.

AU - Lechan, Ronald M.

AU - Tischler, Arthur S.

AU - Popovic, Vera

AU - Miljic, Dragana

AU - Adams, Karen T.

AU - Prall, F. Ryan

AU - Ling, Alexander

AU - Golomb, Meredith

AU - Ferguson, Michael

AU - Nilubol, Naris

AU - Chen, Clara C.

AU - Chew, Emily

AU - Taïeb, David

AU - Stratakis, Constantine A.

AU - Fojo, Tito

AU - Yang, Chunzhang

AU - Kebebew, Electron

AU - Zhuang, Zhengping

AU - Pacak, Karel

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Worldwide, the syndromes of paraganglioma (PGL), somatostatinoma (SOM) and early childhood polycythemia are described in only a few patients with somatic mutations in the hypoxia-inducible factor 2 alpha (HIF2A). This study provides detailed information about the clinical aspects and course of 7 patients with this syndrome and brings into perspective these experiences with the pertinent literature. Six females and one male presented at a median age of 28 years (range 11-46). Two were found to have HIF2A somatic mosaicism. No relatives were affected. All patients were diagnosed with polycythemia before age 8 and before PGL/SOM developed. PGLs were found at a median age of 17 years (range 8-38) and SOMs at 29 years (range 22-38). PGLs were multiple, recurrent and metastatic in 100, 100 and 29% of all cases, and SOMs in 40, 40 and 60%, respectively. All PGLs were primarily norepinephrine-producing. All patients had abnormal ophthalmologic findings and those with SOMs had gallbladder disease. Computed tomography (CT) and magnetic resonance imaging revealed cystic lesions at multiple sites and hemangiomas in 4 patients (57%), previously thought to be pathognomonic for von Hippel-Lindau disease. The most accurate radiopharmaceutical to detect PGL appeared to be [18F]-fluorodihydroxyphenylalanine ([18F]-FDOPA). Therefore, [18F]-FDOPA PET/CT, not [68Ga]-(DOTA)-[Tyr3]-octreotate ([68Ga]-DOTATATE) PET/CT is recommended for tumor localization and aftercare in this syndrome. The longterm prognosis of the syndrome is unknown. However, to date no deaths occurred after 6 years follow-up. Physicians should be aware of this unique syndrome and its diagnostic and therapeutic challenges.

AB - Worldwide, the syndromes of paraganglioma (PGL), somatostatinoma (SOM) and early childhood polycythemia are described in only a few patients with somatic mutations in the hypoxia-inducible factor 2 alpha (HIF2A). This study provides detailed information about the clinical aspects and course of 7 patients with this syndrome and brings into perspective these experiences with the pertinent literature. Six females and one male presented at a median age of 28 years (range 11-46). Two were found to have HIF2A somatic mosaicism. No relatives were affected. All patients were diagnosed with polycythemia before age 8 and before PGL/SOM developed. PGLs were found at a median age of 17 years (range 8-38) and SOMs at 29 years (range 22-38). PGLs were multiple, recurrent and metastatic in 100, 100 and 29% of all cases, and SOMs in 40, 40 and 60%, respectively. All PGLs were primarily norepinephrine-producing. All patients had abnormal ophthalmologic findings and those with SOMs had gallbladder disease. Computed tomography (CT) and magnetic resonance imaging revealed cystic lesions at multiple sites and hemangiomas in 4 patients (57%), previously thought to be pathognomonic for von Hippel-Lindau disease. The most accurate radiopharmaceutical to detect PGL appeared to be [18F]-fluorodihydroxyphenylalanine ([18F]-FDOPA). Therefore, [18F]-FDOPA PET/CT, not [68Ga]-(DOTA)-[Tyr3]-octreotate ([68Ga]-DOTATATE) PET/CT is recommended for tumor localization and aftercare in this syndrome. The longterm prognosis of the syndrome is unknown. However, to date no deaths occurred after 6 years follow-up. Physicians should be aware of this unique syndrome and its diagnostic and therapeutic challenges.

KW - HIF2A mutation

KW - Paraganglioma

KW - Pheochromocytoma

KW - Polycythemia

KW - Somatostatinoma

UR - http://www.scopus.com/inward/record.url?scp=84997787320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997787320&partnerID=8YFLogxK

U2 - 10.1530/ERC-16-0231

DO - 10.1530/ERC-16-0231

M3 - Article

VL - 23

SP - 899

EP - 908

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 12

ER -